# uMed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/umed

- Industry: Software
- Headquarters: London, UK
- Website: www.umed.io
- Total disclosed funding: $17M
- Latest round: Series A (Jul 5, 2023)
- Investors on record: 4

## About

uMed, based in the UK, is a technology company that enhances medical research through consented patient data collection, fostering improved patient outcomes and insights for healthcare professionals and life sciences researchers.Founded in 2017, uMed is based in London, UK, and specializes in building consented patient cohorts for research. The company has conducted a total of 2 deals, with the most recent deal occurring on July 5, 2023, when it secured GBP 9.8 million in Series A funding from investors including 11.2 Capital, AlbionVC, Delin Ventures, and Playfair Capital. The CEO of uMed is Hamlet Asatryan, with Matt Wilson as its founder.uMed specializes in building consented patient cohorts that enhance research capabilities and generate insights aimed at improving patient outcomes. Central to their offerings is the ACCESS Research Platform, which allows researchers to gather custom patient data through the remote collection of electronic health records, clinical outcomes, patient-generated data, and biosamples. This platform directly addresses critical evidence gaps across therapy areas by providing access to deeply characterized patient cohorts that match specific research requirements. uMed's services cater primarily to healthcare professionals, life sciences researchers, and patients, facilitating a streamlined approach to participation in medical research. Their operations extend across major markets in the United States, Canada, and the United Kingdom.uMed's revenue model is structured around partnerships and collaborations with healthcare providers, researchers, and life science companies. The company engages in B2B transactions, providing access to their ACCESS Research Platform and associated data services. Through these partnerships, clients can leverage uMed’s extensive patient data and insights to conduct research studies effectively, often involving subscription-based pricing for ongoing access to these resources. The company also supports research initiatives with grant funding opportunities, which can generate additional revenue streams. By enabling healthcare providers to participate in research with minimal workload and offering scalable solutions to life sciences researchers, uMed creates a sustainable business model focused on enhancing clinical outcomes and advancing medical research.In July 2023, uMed raised GBP 9.8 million in Series A funding to support its growth strategy, which includes expanding operations in the North American market and bolstering participation in clinical trials. The company aims to extend the reach of its landmark cohort program in Parkinson’s Disease, Access-PD, leveraging the recent funding to enhance its offerings and market presence.

## Funding rounds

- Series A, Jul 5, 2023, $13M — Playfair Capital, 11.2 Capital, Delin Ventures, AlbionVC
- Seed, Nov 2, 2020, $4.8M — Playfair Capital, 11.2 Capital, Delin Ventures, AlbionVC

## Investors

- Playfair Capital (https://capitalatlas.ai/funds/playfair-capital) — Seed, Series A
- 11.2 Capital (https://capitalatlas.ai/funds/11-2-capital) — Seed, Series A
- Delin Ventures (https://capitalatlas.ai/funds/delin-ventures) — Seed, Series A
- AlbionVC — Seed, Series A